Skip to main content
Gastro Hep Advances logoLink to Gastro Hep Advances
. 2025 Jun 20;4(10):100733. doi: 10.1016/j.gastha.2025.100733

Delayed Gastric Emptying Neither Contributes to Gastroesophageal Reflux nor Disease Severity in Patients With Respiratory Disease

Jessica Bradley 1, Caroline Olson 2, Ali Alghubari 1,3, Ramsah Cheah 1, Sadia Z Shah 4, Augustine S Lee 5, Kenneth R DeVault 2, Lesley A Houghton 1,2,∗
PMCID: PMC12410532  PMID: 40917766

Abstract

Background and Aims

Gastroesophageal reflux (GER) is common and thought to contribute to disease progression in patients with respiratory disease. Delayed gastric emptying (DGE) can increase GER in patients with GER disease, but its effect in patients with respiratory disease, and how differing lung structure (eg, scarring, inflammation) and mechanics (eg, decreased thoracic pressure in restrictive disease, increased abdominal pressure in obstructive disease) influences this is unknown. Our aim was to understand these interrelationships and association with pulmonary function in patients with chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease (non-IPF ILD).

Methods

We prospectively recruited 22 COPD (aged 34–75 years), 33 IPF (45–74 years), and 19 non-IPF ILD (37–74 years) patients who underwent gastric emptying studies, high resolution impedance manometry, 24-hr pH-impedance, and pulmonary function testing, as part of routine lung transplantation assessment.

Results

Gastric emptying was delayed in a total of 20(27%) patients; 5(23%) with COPD, 8(24%) with IPF and 7(37%) with non-IPF ILD. Notably, all 7 non-IPF ILD patients with DGE had nonspecific interstitial pneumonia (NSIP; ie, 70% of NSIP patients; P < .02 compared with other groups). DGE irrespective of disease type was not associated with increased acid exposure time, total bolus exposure time or number of reflux events. Furthermore, DGE was not associated with higher intra-abdominal pressure, specific esophageal dysmotility, or worse pulmonary function in any of the respiratory diseases.

Conclusion

Significantly more NSIP patients have DGE compared with other respiratory diseases. Irrespective of this, DGE had little effect on GER or pulmonary function in any of the respiratory diseases.

Keywords: esophageal motility, gastric emptying, lung mechanics, obstructive lung disease, reflux, restrictive lung disease

Graphical abstract

graphic file with name ga1.jpg

Introduction

Gastroesophageal reflux (GER) is common and thought to contribute to worse pulmonary function and progression of disease in patients with respiratory disorders.1 The detection of gastric pepsin and/or bile in bronchoalveolar lavage fluid (BALF) or sputum supports the occurrence of microaspiration of refluxate in these patients.2, 3, 4 Moreover, studies in patients with idiopathic pulmonary fibrosis (IPF) have reported that the degree of fibrosis correlates with BALF concentrations of both pepsin and bile acid2, although similar observations have not been reported in patients with chronic obstructive pulmonary disease (COPD).3

Various factors can predispose subjects to increased exposure of the esophagus to reflux, including ineffective esophageal motility (IEM),5, 6, 7 abnormal lung mechanics and breathing patterns,8 and delayed gastric emptying.9, 10, 11, 12 Studies report that between approximately 27% and 58% of patients with restrictive lung disease (RLD) and obstructive lung disease (OLD) lung disease exhibit IEM.13, 14, 15 IPF patients with IEM have more severe pulmonary function and more proximal reflux compared with patients with normal motility.13 In patients with COPD these associations with esophageal dysmotility are less clear, and although reflux has been associated with frequent exacerbation, IEM and objective measurements of reflux have not been shown to associate with worse pulmonary function.14,16 Greater negative intrathoracic pressures in IPF patients with IEM also inversely correlates with the number of reflux events reaching the proximal esophagus, and positively with pulmonary function (ie, the greater the negative intrathoracic pressure, the lower the percent predicted forced vital capacity [FVC] and percent predicted forced expiratory volume in 1 second [FEV1]).13 A similar negative correlation between intrathoracic pressure and proximal acid exposure has been reported in patients with COPD.17 The discoordination between the phases of breathing and swallowing may also impact esophageal function and reflux clearance. In healthy volunteers, increasing the frequency of breathing and voluntarily changing the contributions of the ribcage and abdomen can influence intraesophageal pressure and thus potentially reflux,18 whereas hyperventilation and partial expiration can impair esophagogastric junction relaxation and esophageal peristalsis, delaying esophageal transit and clearance.19

Lastly, gastric emptying has been shown to be delayed in up to 50% of patients with respiratory disease,15,20, 21, 22, 23, 24, 25 with the prevalence being no different between those with RLD and OLD.15,20,21 One study however, did report that in respiratory patients with delayed gastric emptying, there was a tendency for more patients to have cystic fibrosis (CF) or non-scleroderma non-IPF interstitial lung disease (ILD), and less likely to have IPF.22 This study also looked at the relationship between delayed gastric emptying and lung function, reporting that those with delayed emptying were more likely to have moderate to severe disease (i.e. FEV1<60% predicted).22 However, the percentage of patients with moderate/severe disease was high in both those with and without delayed gastric emptying (100% vs 81%), and the cohort was a mixture of patients with CF, ILD, COPD, scleroderma, sarcoidosis, and IPF. Thus, whether delayed gastric emptying is associated with increased reflux and/or worse pulmonary function, in those with restrictive compared with obstructive disease, and between different restrictive diseases, such as IPF and non-IPF ILD, and how the contrasting respiratory mechanics seen in these different disease types, along with esophageal dysmotility, influences the impact of delayed gastric emptying on lung function is unknown. This is important, as it is unclear whether delayed gastric emptying, especially if patients are asymptomatic, should be treated due to concern of potential increased GER and its aspiration into the lungs. Moreover, whether certain patients with end-stage lung disease should be prioritized more than others who undergo lung transplantation (LTx) based on gastric emptying is unclear.

Our aim was therefore to examine the interrelationships between gastric emptying, esophageal motility and lung mechanics, and their impact on GER and lung function in patients with COPD, IPF, and non-IPF ILD.

Materials and Methods

Patients

154 consecutive patients were referred for gastric emptying studies, esophageal high resolution impedance manometry (HRIM), and 24-hr pH-impedance (MII-pH) as part of their routine clinical work-up for LTx at Mayo Clinic, Florida between November 2016 and October 2022. 80 patients who did not complete all tests were excluded. We therefore analyzed complete data from the 74 remaining patients (median age 64 (range 34–75) years, 25 (33.8%) females, mean body mass index 28.1 (95% confidence interval; 27.1–29.1). All medications were stopped 48 hrs prior to the tests. Patients had a diagnosis of COPD, IPF, or non-IPF ILD confirmed by a multidisciplinary panel prior to inclusion in the study. Patients with scleroderma, previous lung or gastrointestinal surgery, or current lung or gastrointestinal malignancy, were excluded.

Gastric Emptying Scintigraphy

Gastric emptying was measured using the established, validated, scintigraphic technique employed by Mayo Clinic.26 After an overnight fast of at least 8 hours, patients ate a 99mTc-labeled meal of two scrambled eggs (standard size), 1 slice of whole wheat bread and 1 glass (240ml) of skimmed (<1% fat) milk (320 kcal, 30% fat). Abdominal images were obtained with a dual anterior/posterior gamma camera. Following consumption of the standardized meal, 2-minute static images were obtained. The patient then returned for scanning at 1, 2, and 4 hours.26

HRIM

HRIM was performed using a solid-state catheter with 36 pressure sensors 1cm apart and 18 impedance sensors (Medtronic, Shoreview, MN). The catheter was positioned transnasally with distal sensors for both pressure and impedance in the proximal stomach. Following at least a 30s baseline to identify the upper esophageal sphincter and lower esophageal sphincter (LES), ten 5 ml saline swallows were given at least 30s apart with the patient supine.27

Impedance tracings were evaluated for each swallow and bolus clearance assessed using both colorized contour functions and superimposed impedance tracings.28 Subjects were classified as complete bolus transit when clearance was seen in ≥80% of swallows.29

MII-pH

MII-pH was performed using a single antimony pH probe (5cm above the LES) with 8 impedance electrodes (Sandhill Scientific, CO).30

Pulmonary Function Testing

Pulmonary function data was obtained from patient records at the time of gastric emptying assessment, including FEV1, FVC, and FEV1/FVC ratio. Respiratory disease severity was categorized as severe if FEV1 ≤50% predicted, moderate if FEV1 51%–79%, and mild if FEV1 ≥80% predicted. Percentage predicted values were obtained using patient age, height and ethnicity as per American Thoracic Society/European Respiratory Society recommendations.31

Data Analysis

Gastric emptying

Abdominal images at 1, 2, and 4hr post-meal were evaluated, and the data at 4hrs used to categorize patients as having either normal gastric emptying (retention ≤10%) or delayed gastric emptying (retention >10%).32,33

HRIM

ManoVIEW analysis software (v3.01; Medtronic, Shoreview, NM) was used to manually analyze the recordings. Esophageal motility was classified based upon Chicago Classification (CCv4.0).27 Each 5ml swallow was evaluated to determine the following: 1) integrated relaxation pressure, 2) distal contractile integral, 3) distal latency, and 4) isobaric contour (pressurization).28 Contractile pattern was classified as normal, weak, failed peristalsis, fragmented, or hypercontractile swallow.27

CCv4.0 diagnoses included the following: 1) achalasia or esophagogastric junction outflow obstruction (EGJOO), and 2) disorders of peristalsis, such as absent contractility, distal esophageal spasm, hypercontractile esophagus (single peak hypercontractile swallow, Jackhammer esophagus and hypercontractile LES), and IEM.27 As HRIM was performed in very sick patients requiring lung transplant, with most tests carried out before the publication of CCv4.0, additional provocation or alternate position testing to confirm EGJOO was not performed. We thus use the term ‘inconclusive EGJOO’ to describe patients with suspected EGJOO.

Thoracoabdominal pressure gradient (TAPG)

TAPG was calculated by subtracting the intra-abdominal pressure (intra-AP; proximal stomach 1cm below the lower border of the LES and referenced to atmospheric pressure) from the mean intrathoracic pressure (distal esophagus between 1 and 5cm above the upper border of the LES and referenced to atmospheric pressure) during inspiration. LES pressure during inspiration, referenced to the pressure at the level of the intra-AP (ie, 1 cm below the lower border of the LES), was also measured, and an adjusted thoracoabdominal pressure gradient (aTAPG) was calculated by subtracting lower esophageal sphincter pressure (LESP) from the TAPG during inspiration. A cutoff value of aTAPG to predict the risk of reflux was set at >0mmHg, based on the hypothesis that reflux may occur when TAPG overcomes the LESP.8,13

Esophageal length (EL) and esophageal length index (ELI)

EL was measured from the lower border of the upper esophageal sphincter to the upper border of LES at end-inspiration. ELI was calculated by dividing EL (centimeters) by height (meters).15

MII-pH

Data were manually analysed (BioVIEW Analysis software, Sandhill Scientific, CO) excluding meals for reflux episodes based on retrograde impedance decrease to 50% of baseline in at least two distal adjacent channels. Abnormalities in reflux exposure were as previously defined.13,34 In addition, the main meal during the study was identified and total bolus exposure time (TBET) 4hrs post-meal was recorded.

Statistics

Differences between disease cohorts with respect to continuous measures were assessed using the 1-way analysis of variance test or Kruskal-Wallis test, followed by Student’s 2-sample t tests or Mann-Whitney U test, as appropriate based on the distribution of data. We adjusted for multiple comparisons using a Bonferroni correction. Binary logistic regression was used to determine the impact of diagnosis, and proton pump inhibitor (PPI) and immunomodulator use on gastric emptying, defined as either normal (4hr post-meal retention ≤10%) or delayed (4hr post-meal >10% retention). Categorical measures between groups were evaluated using either the chi square or Fishers Exact tests, depending on group size. Relationships between continuous variables were assessed using scatterplots and quantified using Pearson’s correlation or Spearman rank correlation. Significance was evaluated at the 2-tailed, P value of <0.05 taken as significant.

Results

Of the 74 patients recruited, 22(30%) COPD (median age 62 [range, 34–75] years), 33(44%) had IPF (aged 65 [45–74] years), and 19 (26%) non-IPF ILD (aged 60 [37–74] years). Of the non-IPF ILD patients, 10 (53%) had fibrotic nonspecific interstitial pneumonia (NSIP), 5 (26%) chronic hypersensitivity pneumonitis (CHP), and 4 (21%) sarcoidosis. The majority of patients suffered from moderate or severe disease (FEV1% 36 [48.6%] severe, 32 [43.2%] moderate, and 6 [8.1%] mild). Table 1 shows the demographic data, along with medication use in the three cohorts. All tests were completed within a median of 5 days (interquartile range: 2–8 days).

Table 1.

Demographic and Clinical Characteristics

Total n = 74 COPD n = 22 IPF n = 33 Non-IPF ILD n = 19 P value
Agea, y 63.5 (58.0–67.0) 62.0 (58.0–66.0) 65.0 (62.0–68.0) 60.0 (50.0–65.0)c .048
Body mass indexb, kg/m2 28.1 (27.1–29.1) 27.2 (25.2–29.3) 28.8 (27.3–30.2) 28.0 (25.6–30.4) .470
Weighta, kg 79.7 (73.3–91.0) 74.8 (66.5–83.7) 84.7 (77.3–94.2) 78.1 (73.3–89.2) .059
Male, n (%) 49 (66.2%) 10 (45.5%) 27 (81.8%)f 12 (63.2%) .019
Female 25 (33.8%) 12 (54.5%) 6 (18.2%) 7 (36.8%)
Ethnicity n (%)
 White 63 (85.1%) 19 (86.4%) 32 (97.0%) 13 (68.4%) 0.211
 Black 7 (9.5%) 2 (9.1%) 1 (3.0%) 4 (21.0%)
 Asian 2 (2.7%) 1 (4.5%) 0 1 (5.3%)
 Other 2 (2.7%) 0 0 1 (5.3%)
Tobacco use n (%)
 Never smoked 29 (39.2%) 1 (4.5%) 13 (39.4%)f 15 (78.9%)d,g <0.001
 Ex-smoker 45 (60.8%) 21 (95.5%) 20 (60.6%) 4 (21.1%)
 Current smoker 0 0 0 0
Medication use n (%)
 PPIs 29 (39.2%) 5 (22.7%) 16 (48.5%) 8 (42.1%) 0.152
 Opiates 2 (2.7%) 0 2 (6.1%) 0 0.279
 ICS, LAMA, LABA, or combination inhalers 35 (47.3%) 20 (90.9%) 7 (21.2%)g 8 (42.1%)f <0.001
 Immunomodulatorsh 11 (14.9%) 2 (9.1%) 3 (9.1%) 6 (31.6%) 0.060
 PDE-5 inhibitors 4 (5.4%) 0 1 (3.0%) 3 (15.8%) 0.060
 Antifibrotics 24 (32.4%) 0 20 (60.6%)g 4 (21.1%)d,e <0.001
Comorbidities n (%)
 Diabetes mellitus 5 (6.8%) 0 3 (9.1%) 2 (10.5%) 0.315
 Hiatus hernia 3 (4.1%) 2 (9.5%) 1 (3%) 0 0.312
Pulmonary function tests
 FEV1a, % 51.0 (33.0–66.1) 28.0 (22.0–43.0) 57.0 (47.1–67.0)g 58.0 (37.0–72.0)f <0.001
 FVCa, % 57.7 (46.0–66.0) 64.0 (54.0–77.0) 52.0 (43.0–61.0)f 57.3 (39.0–67.0) <0.001
 FEV1/FVC ratioa 0.82 (0.52–0.87) 0.37 (0.28–0.43) 0.84 (0.81–0.89)g 0.85 (0.77–0.89)g <0.001
 TLCa, % 61.9 (50–108) 127.0 (108–139) 52.0 (47–58)g 57.8 (42–64)g <0.001
 RVa, % 65.6 (50–170) 208.5 (154–270) 53.5 (46–59)g 57.0 (49–72)g <0.001
Proportion with moderate to severe disease n (%)
 FEV1, % (<80%) 68 (91.9%) 20 (90.9%) 31 (93.9%) 17 (89.5%) 0.834
 FVC, % (<80%) 68 (91.9%) 17 (77.3%) 33 (100%)f 18 (94.7%) 0.009
Domiciliary oxygen n (%)
 Domiciliary oxygen 59 (79.7%) 19 (86.4%) 28 (84.8%) 12 (63.2%) 0.113
Esophageal length & index
 Esophageal lengthb, cm 24.1 (23.3–24.9) 26.8 (25.6–28.1) 22.0 (21.1–23.0)g 24.4 (23.2–25.7)d,f <0.001
 Esophageal length indexb 14.1 (13.7–14.6) 15.9 (15.2–16.6) 12.8 (12.3–13.4)g 14.3 (13.5–15.0)d,f <0.001

Results expressed as: Median (IQR), Mean (95% CI), and number (%) for categorical variables. 95% CI, 95% confidence interval; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroid; IQR, interquartile range; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonists; PDE-5 inhibitors, phosphodiesterase-5 inhibitors; PPI, proton pump inhibitor; RV, residual volume; TLC, total lung capacity.

a

Median (IQR).

b

Mean (95% CI).

c

P < .05 compared with IPF.

d

P < .01 compared with IPF.

e

P < .05 compared with COPD.

f

P < .01 compared with COPD.

g

P < .001 compared with COPD.

h

Immunomodulators include mycophenolate mofetil, azathioprine.

Gastric Emptying

Gastric emptying was delayed in a total of 20 (27%) patients; 5 (23%) with COPD, 8 (24%) with IPF, and 7 (37%) with non-IPF ILD (Table 2). Subanalysis of the non-IPF ILD patients revealed that all seven patients with delayed gastric emptying had fibrotic NSIP, which was significantly higher than the percentages seen in patients with CHP (P = .026) and sarcoidosis (P = .070). Furthermore, a greater proportion of non-IPF ILD patients with fibrotic NSIP had delayed gastric emptying compared with COPD (P = .018) and IPF (P = .019) patients.

Table 2.

Gastric Emptying in Patients With COPD, IPF, and Non-IPF ILD, Including Fibrotic Nonspecific Interstitial Pneumonia (NSIP), Chronic Hypersensitivity Pneumonitis (CHP), and Sarcoidosis

Total n = 74 COPD n = 22 IPF n = 33 Non-IPF ILD P value
Total n = 19 Fibrotic NSIP n = 10 CHP n = 5 Sarcoidosis n = 4
Gastric emptying findings
 Normal GE, n (%) 54 (73.0%) 17 (77.3%) 25 (75.8%) 12 (63.2%) 3 (30%) 5 (100%) 4 (100%) .011
 Delayed GE 20 (27.0%) 5 (22.7%) 8 (24.2%) 7 (36.8%) 7 (70%)b 0 0
 1 h % retentiona 69 (61–76) 66 (55–72) 69 (63–74) 72 (63–76) 71 (63–76) 76 (70–76) 65 (54–78) .441
 2 h % retentiona 44 (31–53) 41 (24–52) 43 (32–50) 51 (38–58) 53 (38–68) 47 (46–51) 35 (22–52) .199
 4 h % retentiona 5 (1–11) 5 (1–9) 4 (1–10) 9 (2–17) 17 (2–38) 8 (6–9) 4 (2–7) .177

Results expressed as: Median (IQR), and number (percentage) for categorical variables.

CHP, chronic hypersensitivity pneumonitis; GE, gastric emptying; IQR, interquartile range; NSIP, nonspecific interstitial pneumonia.

a

Median (IQR).

b

P < .05 compared with COPD, IPF, and CHP.

Indeed logistic regression analysis using diagnosis (IPF, COPD, fibrotic NSIP, CHP, and sarcoid), PPI, and immunomodulator use, identified fibrotic NSIP but not PPI or immunomodulator use, to be an independent predictor of delayed gastric emptying (OR 10.6, 95% confidence interval 1.8–63.8; P = .010).

Of the 5 patients with diabetes, 2 patients (both IPF) had delayed gastric emptying.

Association With Reflux

Examining the whole cohort showed that there were no statistically significant differences in any of the reflux parameters between patients who had normal and delayed gastric emptying (Table 3). Similarly, examining the disease groups separately showed no statistically significant differences in reflux parameters between patients with normal and delayed gastric emptying in COPD, non-IPF ILD, or IPF (Table 4, Table 5, Table 6) (NB that all non-IPF ILD patients with delayed gastric emptying had fibrotic NSIP). This also applied to TBET during the 4hrs post-main meal of the day. However, patients with non-IPF ILD who had delayed gastric emptying did tend to have a higher proportion of distal reflux events reaching the proximal esophagus (P = .068) than patients with normal gastric emptying (Table 6).

Table 3.

Comparison of Reflux Parameters, Thoracic and Abdominal Pressures, Esophageal Motility, and Esophageal Length/Esophageal Length Index in Patients With Normal and Delayed Gastric Emptying, in the Total Cohort of Respiratory Patients


Normal gastric emptying
Delayed gastric emptying
P value
Total cohort n = 54 n = 20
MII-pH findings
 AETa, % 1.6 (0.3–5.7) 3.2 (1.0–9.4) .092
 Pts with abnormal AET (>6%), n (%) 13 (24.1%) 7 (35.0%) .347
 TBETa, % 1.4 (0.4–2.0) 1.2 (0.7–2.5) .860
 Pts with abnormal TBET (≥1.4%), n (%) 28 (51.9%) 8 (40%) .365
 Total no. of distal eventsa, n 36 (19–49) 29 (19–45) .507
 Pts with abnormal no. of distal events (>80), n (%) 2 (3.7%) 0 1.000
 Total no. of proximal eventsa, n 10 (3–20) 14 (3–19) .976
 Pts with abnormal no. of proximal events (>31), n (%) 7 (13.0%) 1 (5%) .435
 % of distal events reaching proximal esophagusa, % 32.9 (17.5–51.3) 40.0 (23.0–52.1) .473
 4 h post-meal TBETa, % 1.9 (1.1–3.9) 1.6 (0.6–3.2) .648
Pulmonary function tests
 FEV1a, % 49.5 (31.0–63.0) 54.5 (36.5–71.5) .309
 FVCa, % 55.0 (43.0–65.0) 60.0 (48.5–70.0) .450
 FEV1/FVC ratioa 0.83 (0.44–0.87) 0.79 (0.60–0.87) .918
 TLC, %a 62.0 (50.0–106.5) 60.0 (47.0–111.0) .718
 RV, %a 71.5 (50.0–182.0) 57.5 (50.0–94.0) .565
Thoracoabdominal pressure gradients
 Abdominal pressure, mmHgb 18.1 (15.9–20.4) 18.5 (11.0–23.1) .910
 Inspiratory LES pressure, mmHgb 60.8 (52.5–69.2) 61.6 (45.6–77.6) .930
 Thoracic pressure, mmHgb −1.5 (−3.9 – 0.8) −0.9 (−6.9 – 5.0) .819
 TAPG, mmHgb 19.7 (17.3–22.1) 19.4 (14.3–24.6) .913
 Adjusted TAPG, mmHgb −41.2 (−49.7 – −32.6) −42.2 (−56.7 – −27.6) .903
CCv4 motility findings n (%)
 Normal 35 (64.8%) 13 (65.0%) .839
 IEM 6 (11.1%) 2 (10%)
 iEGJOO 10 (18.5%) 5 (25%)
 DES 1 (1.9%) 0
 Hypercontractile 2 (3.7%) 0
LES findings
 LES basal pressure, mmHga 37.1 (24.9–49.9) 34.7 (29.5–43.9) .688
 Median IRP, mmHgb 10.8 (9.3–12.3) 11.3 (8.7–13.9) .730
 LES length, cma 5.0 (4.0–5.7) 4.0 (4.0–5.0) .291
Incomplete bolus transit
 Incomplete bolus transit, n (%) 43 (79.6%) 15 (75.0%) .753
 IBTa, % 65 (30–90) 64 (23–100) .854
Esophageal length & index
 Esophageal length, cmb 24.2 (23.2–25.2) 23.8 (22.5–25.1) .698
 Esophageal length indexb 14.2 (13.6–14.8) 14.0 (13.3–14.8) .817

Results expressed as: Median (IQR), Mean (95% CI), and number (percentage) for categorical variables.

95% CI, 95% confidence interval; AET, acid exposure time; DES, distal esophageal spasm; IBT, incomplete bolus transit; iEGJOO, inconclusive esophagogastric junction outflow obstruction; IEM, ineffective esophageal motility; IQR, interquartile range; IRP, integrated relaxation pressure; LES, lower esophageal sphincter; MII-pH, 24-h pH-impedance; TAPG, thoracoabdominal pressure gradient; TBET, total bolus exposure time (ie, % of monitored time that the esophagus was exposed to reflux of any nature).

a

Median (IQR).

b

Mean (95% CI).

Table 4.

Comparison of Reflux Parameters, Thoracic and Abdominal Pressures, Esophageal Motility, and Esophageal Length/Esophageal Length Index in Patients With Normal and Delayed Gastric Emptying in Patients With COPD


Normal gastric emptying
Delayed gastric emptying
P value
COPD n = 17 n = 5
MII-pH findings
 AETa, % 1.2 (0.2–3.4) 2.9 (1.3–9.9) .218
 Pts with abnormal AET (>6%), n (%) 2 (11.8%) 2 (40%) .210
 TBET, %a 1.3 (0.9–1.8) 1.0 (0.7–1.1) .283
 Pts with abnormal TBET (≥1.4%), n (%) 8 (47.1%) 0 .115
 Total no. of distal eventsa, n 33 (18–53) 22 (17–29) .543
 Pts with abnormal no. of distal events (>80), n (%) 1 (5.9%) 0 1.000
 Total no. of proximal eventsa, n 10 (4–16) 8 (4–18) .940
 Pts with abnormal no. of proximal events (>31), n (%) 1 (5.9%) 0 1.000
 % of distal events reaching proximal esophagusa, % 41.6 (21.4–51.3) 31.9 (28.6–47.1) .940
 4 h post-meal TBETa, % 1.9 (0.5–3.0) 1.0 (0.8–2.1) .543
Pulmonary function tests
 FEV1a, % 29.0 (22.0–43.0) 24.0 (22.0–38.0) 1.000
 FVCa, % 65.0 (51.0–77.0) 60.0 (58.0–73.0) .704
 FEV1/FVC ratioa 0.37 (0.27–0.44) 0.34 (0.29–0.40) 1.000
 TLCa, % 125.0 (105.0–139.0) 129.3 (114.0–132.0) .649
 RVa, % 191.0 (154.0–270.0) 228.0 (180.0–235.0) .940
Thoracoabdominal pressure gradients
 Abdominal pressure, mmHgb 21.3 (17.3–25.3) 18.1 (2.6–33.7) .495
 Inspiratory LES pressure, mmHgb 67.3 (52.8–81.9) 62.3 (10.5–114.1) .756
 Thoracic pressure, mmHgb 4.6 (0.4–8.8) −0.6 (−11.2 – 10.1) .238
 TAPG, mmHgb 16.7 (13.2–20.3) 18.7 (13.1–24.3) .560
 Adjusted TAPG, mmHgb −50.6 (−65.8 – −35.4) −43.6 (−92.2 – 4.9) .670
CCv4 motility findings n (%)
 Normal 11 (64.7%) 3 (60%) .627
 IEM 2 (11.8%) 0
 iEGJOO 3 (17.6%) 2 (40%)
 DES 0 0
 Hypercontractile 1 (5.9%) 0
LES findings
 LES basal pressure, mmHga 39.1 (28.7–47.9) 33.9 (32.9–38.6) .649
 Median IRP, mmHgb 10.4 (8.0–12.7) 11.8 (4.3–19.4) .569
 LES length, cma 4.0 (4.0–5.0) 4.3 (4.0–4.7) .649
Incomplete bolus transit
 Incomplete bolus Transit, n 14 (82.4%) 3 (60.0%) .548
 IBT, %a 70 (40–90) 60 (20–60) .543
Esophageal length & index
 Esophageal length, cmb 27.4 (26.1–28.8) 24.8 (21.2–26.8) .069
 Esophageal length indexb 16.2 (15.4–17.0) 15.0 (13.1–17.0) .158

Results expressed as: Median (IQR, Mean (95% CI) and number (percentage) for categorical variables.

95% CI, 95% confidence interval; AET, acid exposure time; DES, distal esophageal spasm; IBT, incomplete bolus transit; iEGJOO, inconclusive esophagogastric junction outflow obstruction; IEM, ineffective esophageal motility; IQR, interquartile range; IRP, integrated relaxation pressure; LES, lower esophageal sphincter; MII-pH, 24-h pH-impedance; TAPG, thoracoabdominal pressure gradient; TBET, total bolus exposure time (ie, % of monitored time that the esophagus was exposed to reflux of any nature).

a

Median (IQR).

b

Mean (95% CI).

Table 5.

Comparison of Reflux Parameters, Thoracic and Abdominal Pressures, Esophageal Motility, and Esophageal Length/Esophageal Length Index in Patients With Normal and Delayed Gastric Emptying in Patients With IPF

Normal gastric emptying Delayed gastric emptying P value
IPF n = 25 n = 8
MII-pH findings
 AETa, % 2.1 (0.5–5.7) 1.9 (0.8–7.0) .578
 Pts with abnormal AET (>6%), n (%) 6 (24%) 2 (25%) 1.000
 TBETa, % 1.6 (0.4–2.5) 1.15 (0.5–3.6) .918
 Pts with abnormal TBET (≥1.4%), n (%) 13 (52%) 3 (37.5%) .688
 Total no. of distal eventsa, n 36 (20–61) 35 (19–54) .789
 Pts with abnormal no. of distal events (>80), n (%) 1 (4%) 0 1.000
 Total no. of proximal eventsa, n 15 (3–28) 5 (3–21) .496
 Pts with abnormal no. of proximal events (31), n (%) 6 (24%) 1 (12.5%) .651
 % of distal events reaching proximal esophagusa, % 40.6 (17.5–53.8) 33.0 (12.9–43.2) .636
 4 h post-meal TBETa, % 1.9 (1.1–4.1) 1.6 (0.35–5.95) .853
Pulmonary function tests
 FEV1a, % 57.0 (48.0–65.0) 54.0 (41.2–67.5) .757
 FVCa, % 53.0 (46.0–61.0) 50.5 (35.8–63.5) .821
 FEV1/FVC ratioa 0.84 (0.82–0.89) 0.82 (0.74–0.88) .420
 TLCa, % 51.0 (48.0–57.0) 53.0 (39.0–62.0) .866
 RVa, % 51.5 (46.0–70.0) 55.5 (49.8–57.0) .871
Thoracoabdominal pressure gradients
 Abdominal pressure, mmHgb 15.5 (17.6–19.3) 17.6 (9.9–25.3) .576
 Inspiratory LES pressure, mmHgb 61.0 (47.0–75.0) 62.9 (35.0–90.8) .892
 Thoracic pressure, mmHgb −5.8 (−8.4 – −3.1) −4.0 (−17.3 – 9.3) .760
 TAPG, mmHgb 21.3 (17.1–25.5) 21.6 (13.9–29.2) .945
 Adjusted TAPG, mmHgb −39.7 (−53.6 – −25.8) −41.3 (−71.9 – −10.7) .910
CCv4 motility findings n (%)
 Normal 16 (64%) 6 (75%) .815
 IEM 2 (8%) 1 (12.5%)
 iEGJOO 6 (24%) 1 (12.5%)
 DES 1 (4%) 0
 Hypercontractile 0 0
LES findings
 LES basal pressure, mmHgb 39.9 (32.6–47.3) 36.9 (22.5–51.2) .670
 Median IRP, mmHgb 11.5 (9.2–13.9) 9.1 (4.4–13.9) .297
 LES length, cma 5.0 (4.0–5.7) 4.0 (4.0–4.6) .162
Incomplete bolus transit
 Incomplete bolus transit, n 20 (80.0%) 7 (87.5%) 1.000
 IBTa, (%) 60 (33–90) 55 (33–100) .821
Esophageal length & index
 Esophageal length, cmb 21.7 (20.6–22.8) 23.1 (20.8–25.3) .222
 Esophageal length indexb 12.6 (12.0–12.3) 13.4 (12.0–14.8) .209

Results expressed as: Median (IQR), Mean (95% CI), and number (percentage) for categorical variables.

95% CI, 95% confidence interval; AET, acid exposure time; DES, distal esophageal spasm; IBT, incomplete bolus transit; iEGJOO, inconclusive esophagogastric junction outflow obstruction; IEM, ineffective esophageal motility; IQR, interquartile range; IRP, integrated relaxation pressure; LES, lower esophageal sphincter; MII-pH, 24-h pH-impedance; TAPG, thoracoabdominal pressure gradient; TBET, total bolus exposure time (ie, % of monitored time that the esophagus was exposed to reflux of any nature).

a

Median (IQR).

b

Mean (95% CI).

Table 6.

Comparison of Reflux Parameters, Thoracic and Abdominal Pressures, Esophageal Motility and Esophageal Length/Esophageal Length Index in Patients With Normal and Delayed Gastric Emptying in Patients With Non-IPF ILD


Normal gastric emptying
Delayed gastric emptyingc
P value
Non-IPF ILD n = 12 n = 7
MII-pH findings
 AETa, % 2.7 (0.7–7.6) 4.4 (1.0–22.8) .536
 Pts with abnormal AET (>6%), n (%) 5 (41.7%) 3 (42.9%) 1.000
 TBETa, % 1.4 (0.5–2.3) 2.0 (1.2–2.7) .432
 Pts with abnormal TBET (≥1.4%), n (%) 7 (58.3%) 5 (71.4%) .656
 Total no. of distal eventsa, n 35 (20–43) 34 (21–43) .773
 Pts with abnormal no. of distal events (>80), n (%) 0 0
 Total no. of proximal eventsa, n 7 (4–15) 18 (12–19) .100
 Pts with abnormal no. of proximal events (31), n (%) 0 0
 % of distal events reaching proximal esophagusa, % 21.1 (13.4–37.7) 45.7 (39.1–70.6) .068
 4 h post-meal TBETa, % 2.5 (1.2–4.3) 2.5 (1.0–6.5) .967
Pulmonary function tests
 FEV1a, % 45.5 (37.0–68.5) 71.0 (51.0–78.0) .167
 FVCa, % 46.0 (39.0–65.4) 61.0 (47.0–73.0) .227
 FEV1/FVC ratioa 0.86 (0.72–0.87) 0.85 (0.77–0.91) .967
 TLC, %a 55.9 (45.0–64.0) 60.0 (42.0–64.0) .967
 RV, %a 63.0 (48.0–91.0) 56.0 (49.0–59.0) .536
Thoracoabdominal pressure gradients
 Abdominal pressure, mmHgb 19.2 (16.4–21.9) 19.7 (5.5–33.8) .933
 Inspiratory LES pressure, mmHgb 51.3 (34.4–68.2) 59.6 (27.0–92.1) .570
 Thoracic pressure, mmHgb −1.3 (−7.0 – 4.4) 2.2 (−8.8 – 12.3) .469
 TAPG, mmHgb 20.5 (15.3–25.7) 17.5 (2.4–32.5) .591
 Adjusted TAPG, mmHgb −30.8 (−47.9 – −13.8) −42.1 (−62.2 – −22.0) .359
CCv4 motility findings n (%)
 Normal 8 (66.7%) 4 (57.1%) .613
 IEM 2 (16.7%) 1 (14.3%)
 iEGJOO 1 (8.3%) 2 (28.6%)
 DES 0 0
 Hypercontractile 1 (8.3%) 0
LES findings
 LES basal pressure, mmHga 29.4 (25.1–46.2) 31.5 (27.9–42.0) .711
 Median IRP, mmHgb 9.7 (5.5–14.0) 13.4 (9.0–17.8) .224
 LES length, cmb 4.6 (3.8–5.4) 4.3 (3.2–5.4) .637
Incomplete bolus transit
 Incomplete bolus Transit, n 9 (75.0%) 5 (71.4%) 1.000
 IBT, (%)a 45 (23–84) 80 (12–100) .482
Esophageal length & index
 Esophageal length, cmb 24.7 (23.1–26.3) 24.0 (21.2–26.8) .598
 Esophageal length indexb 14.4 (13.4–15.5) 14.0 (12.7–15.3) .596

Results expressed as: Median (IQR), Mean (95% CI) and number (percentage) for categorical variables.

95% CI, 95% confidence interval; AET, acid exposure time; DES, distal esophageal spasm; IBT, incomplete bolus transit; iEGJOO, inconclusive esophagogastric junction outflow obstruction; IEM, ineffective esophageal motility; IQR, interquartile range; IRP, integrated relaxation pressure; LES, lower esophageal sphincter; MII-pH, 24-h pH-impedance; TAPG, thoracoabdominal pressure gradient; TBET, total bolus exposure time (ie, % of monitored time that the esophagus was exposed to reflux of any nature).

a

Median (IQR).

b

Mean (95% CI).

c

All patients with delayed gastric emptying had fibrotic NSIP.

Association With Thoracic Pressure, Abdominal Pressure, TAPG, and aTAPG

As expected, patients with COPD (20.6 mmHg [16.7–24.5] mmHg) tended to have higher APs than IPF (16.0 mmHg [12.8–19.3] mmHg; P = .072) but not non-IPF ILD (19.4 mmHg [14.8–23.9] mmHg; P = .673) patients. Also patients with IPF (−5.3 mmHg [−8.6–2.0] mmHg) had lower thoracic pressures than COPD (3.4 mmHg [−0.3–7.1] mmHg; P < .001) and non-IPF ILD (0 mmHg [−4.8–4.8] mmHg; P = .059) patients, and thus greater TAPG than COPD (21.4 mmHg [17.9–24.9] mmHg vs 17.2 mmHg [14.3–20.0] mmHg; P = .081) but not non-IPF ILD (19.4 mmHg [13.9–24.9] mmHg) patients. There were no differences between patients with non-IPF ILD and COPD.

However, whether patients with COPD, IPF, or non-IPF ILD had delayed gastric emptying did not significantly affect intra-AP compared with those with normal gastric emptying (Table 3). Likewise, thoracic pressure, TAPG, and aTAPG were not significantly different between those with normal and delayed gastric emptying (Table 3).

Association With Esophageal Motility and Bolus Transit

There were no differences in esophageal motility diagnoses or basal LESP between patients with normal and delayed gastric emptying in patients with COPD, non-IPF ILD, and IPF (Tables 4, 5 and 6). Moreover, the tendency for increased proportion of reflux events to reach the proximal esophagus in non-IPF ILD with delayed gastric emptying was not related to differences in IEM, as only 1 patient with delayed gastric emptying had IEM (Table 3). Similarly, there were no differences in bolus transit between those with delayed and normal gastric emptying (Table 4, Table 5, Table 6).

Association With EL and ELI

ELI was significantly greater in patients with COPD (15.9(15.2–16.0) compared with IPF (12.8(12.3–13.4); P < .001) and non-IPF ILD (14.3(13.5–15.0); P < .001). Non-IPF ILD patients had a higher ELI than IPF patients (P = .002). There were no significant differences in ELI between patients with normal or delayed gastric emptying in the whole cohort, or the separate respiratory groups (Tables 3, 4, 5, and 6).

Association With Pulmonary Function

There was no difference in pulmonary function between patients with normal and delayed gastric emptying in any of the respiratory disease groups (Tables 4, 5 and 6). There were no correlations between 1, 2, or 4 hour % clearance and FEV1%, FVC%, percent predicted total lung capacity%, or percent predicted residual volume% for any of the disease groups.

Discussion

We have shown for the first time that more than two thirds of non-IPF ILD patients with fibrotic NSIP (excluding scleroderma) have delayed gastric emptying, but along with patients with COPD, IPF, and other non-IPF ILD diseases, all of whom have differing lung structure and mechanics, delayed gastric emptying was not associated with increased numbers of reflux events, or worse pulmonary function. Furthermore, delayed gastric emptying did not affect intra-AP, or associate with any particular esophageal motility abnormality in any of the respiratory disease types.

Our observations support those of Derousseau et al22 that patients with non-IPF ILD (along with CF, as expected) appear more prevalent among respiratory patients with delayed compared with normal gastric emptying. That study also reported that patients with delayed gastric emptying (mixed cohort of respiratory disease) pre-LTx were also 3.56 times more likely to develop acute cellular rejection within 1-year post-LTx, which was independent of both pre-LTx lung function and reflux. However, they did not specifically report on the association between delayed gastric emptying and reflux pre-LTx, the latter suggested in other studies to also predict outcome following LTx.20,22 Indeed, out of the 83 patients recruited, only 25 (30%) underwent pH testing, of which only 7 (28%) tested positive for GER, all of whom had normal gastric emptying.22 Moreover, how lung mechanics might influence their findings was not investigated.

Despite excluding patients with scleroderma in our study, we have shown that 70% of patients with fibrotic NSIP have delayed gastric emptying, which was significantly higher than that seen in patients with IPF (24%) and COPD (23%). Why patients with fibrotic NSIP have a high prevalence of delayed gastric emptying is unclear, but NSIP can associate with other connective tissue diseases, and recent studies have reported that patients with gastroparesis symptoms (ie, gastrointestinal, not respiratory patients) can exhibit elevated levels of antinuclear antibodies associated with connective tissue disease, though they showed no association with objective measures of gastric emptying.35,36 Unfortunately, closer examination of the medical records of our fibrotic NSIP patients provided no additional clues, with 4 patients with idiopathic NSIP and 3 with idiopathic inflammatory myositis having delayed emptying, and 1 with rheumatoid related ILD and two with interstitial pneumonia and autoimmune features having normal gastric emptying.

Studies in patients with GER disease have suggested that delayed gastric emptying can increase transient LES relaxations, the main mechanism of GER, mediated by abdominal distension.11,12 In our study, delayed gastric emptying did not increase the number of reflux events entering into the distal esophagus or TBET in any of the three respiratory diseases. However, non-IPF ILD patients with delayed emptying (ie, fibrotic NSIP patients) did tend to exhibit a great proportion of distal reflux events reaching the proximal esophagus. The reason for this is unclear as both abdominal and thoracic pressure along with the TAPG or aTAPG and EL/ELI were no different between those with normal and delayed gastric emptying. Moreover, those with delayed gastric emptying exhibited no more IEM than those with normal gastric emptying, a motility abnormality that has been shown to associate with increased proximal esophageal reflux in patients with IPF.13 Thus, as maybe expected we observed no differences in pulmonary function between those with normal and delayed gastric emptying in any of the three respiratory diseases.

Medications, such as immunomodulators (eg, mycophenolate mofetil and azathioprine) and antifibrotics (eg, nintedanib and pirfenidone) used to treat respiratory disease can cause gastrointestinal side effects, such as nausea, abdominal pain and diarrhea, but the effect of these medications on gastric emptying, as far as we are aware, have never been studied. However, although five (50%) of the fibrotic NSIP patients were taking immunomodulators, their use was not an independent predictor of delayed gastric emptying. Moreover, despite the use of antifibrotics been higher in the IPF and non-IPF ILD patients (as expected), there usage was not associated with delayed gastric emptying compared with nonantifibrotic usage. There was low usage of phosphodiesterase-5 inhibitors, which can delay gastric emptying, with 3 patients with Non-IPF ILD using Tadalafil (2 with NGE, 1 with delayed gastric emptying [DGE]) and 1 patient with IPF using Sildenafil (NGE). DGE was also not related to opiate use, as only two patients with IPF were on these medications. Likewise, although a few patients were on other medications that may affect gastric emptying,32 such as calcium channel blockers (n = 3), azithromycin (n = 4), tricyclic antidepressants (n = 1), insulin (n = 1), loperamide (n = 1) and ondansetron (n = 1), all these medications were stopped 48 hours prior to gastric emptying testing, and all these patients had normal gastric emptying. Lastly, twenty nine patients were taking PPIs, which were stopped prior to investigations, and were shown not to independently predict DGE.

Our observations could have potential important clinical implications as it is generally believed that DGE may increase GER, which in patients with respiratory disease, with additional lung mechanic alterations in both intrathoracic (reduced in RLD) and AP (increased in OLD) could lead to significant enhancement in GER, does not appear to be the case. The rather low prevalence of DGE in patients with COPD, IPF and non-IPF ILD, excluding those with NSIP, suggests the routine practice of pre-LTx gastric emptying testing, especially given the absence of increased reflux in these patients with severe lung disease, may not add value for patients or clinicians. However, what impact DGE might have on mortality or morbidity in those with fibrotic NSIP, despite lack of increased reflux, needs further investigation.

Our study has strengths and limitations. A strength is that we have generated data on particular respiratory disease types and have for the first time investigated associations with reflux, TAPGs, and esophageal motility and length. Another strength is that at the time of this study, gastric emptying testing was routine regardless of symptoms in our center. An obvious limitation is that the numbers of patients with DGE was small in some disease types. As a result, the logistic regression analysis used may have overfitted the data. However, a reasonable number of patients (n = 20; 27%) in the total cohort did have DGE, and to have increased patient numbers in the disease subtypes would have required over 250/300 patients in total to be recruited, numbers difficult to obtain at 1 center. Nevertheless, our observations do prompt recognition by gastroenterologists, pulmonologists, and transplant physicians when considering patients for LTx, and support future larger multicenter studies, taking into account lung structure and mechanics. Symptoms associated with DGE, such as nausea, vomiting, and early satiety, were also not recorded, but previous studies in respiratory patients have shown little association with DGE.21,22,37 We also did not measure sputum and/or BALF gastric pepsin levels, the latter because currently there are substantial methodological concerns about the techniques used to measure these markers,38 and new and better validated tests are needed. Lastly, this is a cross-sectional study, and thus only associations rather than cause and effect between various parameters can be concluded. Note, these were patients with severe respiratory disease, awaiting LTx, and it would not have been possible to follow-up.

Conclusion

Our observations suggest that DGE in patients with respiratory disease does not lead to excessive GER, despite lower intrathoracic pressures in patients with RLD, increased APs in patients with OLD, and differences in esophageal motility and length, or associate with worse pulmonary function. Our finding that a high proportion of patients with fibrotic NSIP have DGE requires further study, and the potential impact this may have on morbidity and mortality.

Acknowledgments

The authors thank Julie Morris, Statistician for her guidance on analysis.

Authors’ Contributions

Jessica Bradley: Conceived and drafted the study; collected the data; analysed and interpreted the data; drafted the manuscript. Caroline Olson: Recruited the patients; collected the data. Ali Alghubari: Collected the data. Ramsah Cheah: Collected the data. Sadia Z Shah: Recruited the patients; collected the data. Augustine S Lee: Recruited the patients; collected the data. Kenneth R DeVault: Conceived and drafted the study; recruited the patients; collected the data. Lesley A Houghton: Conceived and drafted the study; analysed and interpreted the data; drafted the manuscript.

All authors commented on drafts of the paper. All authors approved the final draft of the manuscript.

Footnotes

Conflicts of Interest: These authors disclose the following: Sadia Z Shah: served on the advisory board for Lung Bioengineering Ins. Augustine S Lee has received research funding from United Therapeutics. Lesley A Houghton has acted as a consultant for Pfizer, USA, and served on scientific advisory boards for Ironwood Pharmaceuticals, USA; GSK, UK; and Symprove, UK. The remaining authors disclose no conflicts.

Funding: The authors report no funding.

Ethical Statement: The study was approved by the Mayo Clinic Institutional Review Board (IRB# 18–005280).

Data Transparency Statement: Study data will be made available to other investigators on reasonable request.

Reporting Guidelines: Chicago Classification v4.0.; Lyon Consensus v2.0.; American College of Gastroenterology Clinical Guideline: Gastroparesis.

References

  • 1.Houghton L.A., Lee A.S., Badri H., et al. Respiratory disease and the oesophagus: reflux, reflexes and microaspiration. Nat Rev Gastroenterol Hepatol. 2016;13:445–460. doi: 10.1038/nrgastro.2016.91. [DOI] [PubMed] [Google Scholar]
  • 2.Savarino E., Roberto C., Elisa M., et al. Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J. 2013;42:1322. doi: 10.1183/09031936.00101212. [DOI] [PubMed] [Google Scholar]
  • 3.Lee A.L., Button B.M., Denehy L., et al. Proximal and distal gastro-oesophageal reflux in chronic obstructive pulmonary disease and bronchiectasis. Respirology (Carlton, Vic.) 2014;19:211–217. doi: 10.1111/resp.12182. [DOI] [PubMed] [Google Scholar]
  • 4.Lee A.L., Button B.M., Denehy L., et al. Exhaled breath condensate pepsin: potential noninvasive test for gastroesophageal reflux in COPD and bronchiectasis. Respir Care. 2015;60:244–250. doi: 10.4187/respcare.03570. [DOI] [PubMed] [Google Scholar]
  • 5.Triadafilopoulos G., Tandon A., Shetler K.P., et al. Clinical and pH study characteristics in reflux patients with and without ineffective oesophageal motility (IEM) BMJ Open Gastroenterol. 2016;3:e000126. doi: 10.1136/bmjgast-2016-000126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Rogers B.D., Rengarajan A., Mauro A., et al. Fragmented and failed swallows on esophageal high-resolution manometry associate with abnormal reflux burden better than weak swallows. Neurogastroenterology Motil. 2020;32:e13736. doi: 10.1111/nmo.13736. [DOI] [PubMed] [Google Scholar]
  • 7.Rogers B.D., Rengarajan A., Ribolsi M., et al. Postreflux swallow-induced peristaltic wave index from pH-impedance monitoring associates with esophageal body motility and esophageal acid burden. Neurogastroenterology Motil. 2021;33:e13973–n/a. doi: 10.1111/nmo.13973. [DOI] [PubMed] [Google Scholar]
  • 8.Ayazi S., DeMeester S.R., Hsieh C.-C., et al. Thoraco-abdominal pressure gradients during the phases of respiration contribute to gastroesophageal reflux disease. Dig Dis Sci. 2011;56:1718–1722. doi: 10.1007/s10620-011-1694-y. [DOI] [PubMed] [Google Scholar]
  • 9.Gourcerol G., Benanni Y., Boueyre E., et al. Influence of gastric emptying on gastro-esophageal reflux: a combined pH-impedance study. Neurogastroenterology Motil. 2013;25:800-e634. doi: 10.1111/nmo.12181. [DOI] [PubMed] [Google Scholar]
  • 10.Bensinger A., Clayton S. 420 assessing the prevalence of gastroesophageal reflux in gastroparesis: putting the G back in GERD. Am J Gastroenterol. 2019;114:S247. [Google Scholar]
  • 11.Emerenziani S., Sifrim D. Gastroesophageal reflux and gastric emptying, revisited. Curr Gastroenterol Rep. 2005;7:190–195. doi: 10.1007/s11894-005-0033-x. [DOI] [PubMed] [Google Scholar]
  • 12.Holloway R.H., Hongo M., Berger K., et al. Gastric distention: a mechanism for postprandial gastroesophageal reflux. Gastroenterology. 1985;89:779–784. doi: 10.1016/0016-5085(85)90572-4. [DOI] [PubMed] [Google Scholar]
  • 13.Cheah R., Chirnaksorn S., Abdelrahim A.H., et al. The perils and pitfalls of esophageal dysmotility in idiopathic pulmonary fibrosis. Am J Gastroenterol. 2021;116:1189–1200. doi: 10.14309/ajg.0000000000001202. [DOI] [PubMed] [Google Scholar]
  • 14.Iliaz S., Iliaz R., Onur S.T., et al. Does gastroesophageal reflux increase chronic obstructive pulmonary disease exacerbations? Respir Med. 2016;115:20–25. doi: 10.1016/j.rmed.2016.04.005. [DOI] [PubMed] [Google Scholar]
  • 15.Masuda T., Mittal S.K., Kovács B., et al. Foregut function before and after lung transplant. J Thorac Cardiovasc Surg. 2019;158:619–629. doi: 10.1016/j.jtcvs.2019.02.128. [DOI] [PubMed] [Google Scholar]
  • 16.Bigatao A.M., Herbella F.A.M., Del Grande L.M., et al. Chronic obstructive pulmonary disease exacerbations are influenced by gastroesophageal reflux disease. Am Surg. 2018;84:51–55. [PubMed] [Google Scholar]
  • 17.Del Grande L.M., Herbella F.A., Bigatao A.M., et al. Pathophysiology of gastroesophageal reflux in patients with chronic pulmonary obstructive disease is linked to an increased transdiaphragmatic pressure gradient and not to a defective esophagogastric barrier. J Gastrointest Surg. 2016;20:104–110. doi: 10.1007/s11605-015-2955-4. [DOI] [PubMed] [Google Scholar]
  • 18.Irvin C.G., Sampson M., Engel L., et al. Effect of breathing pattern on esophageal pressure gradients in humans. J Applied Physiology. 1984;57:168–175. doi: 10.1152/jappl.1984.57.1.168. [DOI] [PubMed] [Google Scholar]
  • 19.Mittal R.K., Shaffer H.A., Parollisi S., et al. Influence of breathing pattern on the esophagogastric junction pressure and esophageal transit. Am J Physiol - Gastrointest Liver Physiol. 1995;269:577–583. doi: 10.1152/ajpgi.1995.269.4.G577. [DOI] [PubMed] [Google Scholar]
  • 20.Raviv Y., D'Ovidio F., Pierre A., et al. Prevalence of gastroparesis before and after lung transplantation and its association with lung allograft outcomes. Clin Transplantation. 2012;26:133–142. doi: 10.1111/j.1399-0012.2011.01434.x. [DOI] [PubMed] [Google Scholar]
  • 21.D'Ovidio F., Singer L.G., Hadjiliadis D., et al. Prevalence of gastroesophageal reflux in end-stage lung disease candidates for lung transplant. The Ann Thoracic Surgery. 2005;80:1254–1260. doi: 10.1016/j.athoracsur.2005.03.106. [DOI] [PubMed] [Google Scholar]
  • 22.Derousseau T., Chan W.W., Cangemi D., et al. Delayed gastric emptying in prelung transplant patients is associated with posttransplant acute cellular rejection independent of reflux. J Clin Gastroenterol. 2022;56:e121–e125. doi: 10.1097/MCG.0000000000001502. [DOI] [PubMed] [Google Scholar]
  • 23.Cangemi D., Derousseau T., Gavini S. Prevalence of gastroparesis among patients undergoing pre-lung transplantation evaluation: 1225. Am J Gastroenterol. 2017;112 [Google Scholar]
  • 24.Pauwels A., Blondeau K., Mertens V., et al. Gastric emptying and different types of reflux in adult patients with cystic fibrosis: gastric emptying and reflux in cystic fibrosis. Aliment Pharmacol Therapeutics. 2011;34:799–807. doi: 10.1111/j.1365-2036.2011.04786.x. [DOI] [PubMed] [Google Scholar]
  • 25.Bodet-Milin C., Querellou S., Oudoux A., et al. Delayed gastric emptying scintigraphy in cystic fibrosis patients before and after lung transplantation. J Heart Lung Transplant. 2006;25:1077–1083. doi: 10.1016/j.healun.2006.04.013. [DOI] [PubMed] [Google Scholar]
  • 26.Camilleri M., Zheng T., Vosoughi K., et al. Optimal measurement of gastric emptying of solids in gastroparesis or functional dyspepsia: evidence to establish standard test. Gut. 2023;72:2241–2249. doi: 10.1136/gutjnl-2023-330733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Yadlapati R., Kahrilas P.J., Fox M.R., et al. Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0. Neurogastroenterol Motil. 2021;33 doi: 10.1111/nmo.14058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Roman S., Lin Z., Fau - Kwiatek M.A., et al. Weak peristalsis in esophageal pressure topography: classification and association with Dysphagia. Am J Gastroenterol. 2010;106:349–356. doi: 10.1038/ajg.2010.384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Tutuian R., Vela M.F., Balaji N.S., et al. Esophageal function testing with combined multichannel intraluminal impedance and manometry: multicenter study in healthy volunteers. Clin Gastroenterol Hepatol. 2003;1:174–182. doi: 10.1053/cgh.2003.50026. [DOI] [PubMed] [Google Scholar]
  • 30.Almansa C., Smith J.A., Morris J., et al. Weak peristalsis with large breaks in chronic cough: association with poor esophageal clearance. Neurogastroenterology Motil. 2015;27:431–442. doi: 10.1111/nmo.12513. [DOI] [PubMed] [Google Scholar]
  • 31.Graham B.L., Steenbruggen I., Miller M.R., et al. Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement. Am J Respiratory Critical Care Med. 2019;200:e70–e88. doi: 10.1164/rccm.201908-1590ST. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Camilleri M., Kuo B., Nguyen L., et al. ACG clinical guideline: gastroparesis. Am J Gastroenterol. 2022;117:1197–1220. doi: 10.14309/ajg.0000000000001874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Pasricha P.J., Grover M., Yates K.P., et al. Functional dyspepsia and gastroparesis in tertiary care are interchangeable syndromes with common clinical and pathologic features. Gastroenterol. 2021;160:2006–2017. doi: 10.1053/j.gastro.2021.01.230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Gyawali C.P., Yadlapati R., Fass R., et al. Updates to the modern diagnosis of GERD: lyon consensus 2.0. Gut. 2024;73:361–371. doi: 10.1136/gutjnl-2023-330616. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Chaudhary D., Jiang Y., Khan F., et al. Evaluating autoimmune markers in relation to gastrointestinal measures in patients with symptoms of gastroparesis. J Clin Gastroenterol. 2024 doi: 10.1097/MCG.0000000000002062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Parkman H.P., Van Natta M.L., Makol A., et al. Prevalence and clinical correlates of antinuclear antibody in patients with gastroparesis. Neurogastroenterol Motil. 2022;34:e14270. doi: 10.1111/nmo.14270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Hauser B., De Schepper J., Malfroot A., et al. Gastric emptying and gastro-oesophageal reflux in children with cystic fibrosis. J Cystic Fibrosis. 2016;15:540–547. doi: 10.1016/j.jcf.2015.12.015. [DOI] [PubMed] [Google Scholar]
  • 38.Li Y., Xu G., Zhou B., et al. Effects of acids, pepsin, bile acids, and trypsin on laryngopharyngeal reflux diseases: physiopathology and therapeutic targets. Eur Arch Otorhinolaryngol. 2022;279:2743–2752. doi: 10.1007/s00405-021-07201-w. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gastro Hep Advances are provided here courtesy of Elsevier

RESOURCES